Olmesartan-associated duodenal villous atrophy, an emerging clinical issue.
Intern Med J
; 50(5): 624-626, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-32431039
ABSTRACT
Duodenal villous atrophy with olmesartan was described in 2012, 10 years following registration of olmesartan. Clinical features are severe watery diarrhoea, usually occurring in association with weight loss. Onset is delayed, with a mean duration of prior exposure to olmesartan of 3 years. Diagnosis may be delayed. Symptoms resolve over weeks following cessation of olmesartan. Epidemiological studies suggest increased risk with olmesartan, rather than a class effect of all angiotensin receptor blockers. Post-marketing surveillance for drug safety remains important.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bloqueadores do Receptor Tipo 1 de Angiotensina II
/
Hipertensão
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article